An Open-Label, Randomized, Single-Dose, Two-Way Crossover Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz), Manufactured At Zwickau Versus Vega Baja, In Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2013
At a glance
- Drugs Fesoterodine (Primary)
- Indications Overactive bladder
- Focus Pharmacokinetics
- Sponsors Pfizer
- 06 Jul 2012 New source identified and integrated (German Clinical Trials Register: DRKS00003982).
- 31 May 2011 Actual end date changed from Jul 2009 to Aug 2009 as reported by ClinicalTrials.gov.
- 09 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.